As the COVID-19 pandemic progresses, obtaining information on symptoms dynamics is of
essence. Here, we extracted data from primary-care electronic health records and nationwide …

Background On July 30, 2021, the administration of a third (booster) dose of the BNT162b2
messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 …

The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely …

Objectives To determine the clinical sequelae of long covid for a year after infection in patients
with mild disease and to evaluate its association with age, sex, SARS-CoV-2 variants, and …

We describe a data-driven approach, using a combination of machine learning algorithms
to solve the 2011 Physionet/Computing in Cardiology (CinC) challenge - identifying data …

Background: Reliably identifying patients at increased risk for coronavirus disease (COVID-19)
complications could guide clinical decisions, public health policies, and preparedness …

Objective The use of risk prediction models grows as electronic medical records become widely
available. Here, we develop and validate a model to identify individuals at increased risk …

Background Although BNT162b2 vaccine-efficacy analyses have been published, the
effectiveness of the vaccine in preventing coronavirus disease 2019 given confirmed exposure …

Objective Adolescents’ mental health was severely compromised during the COVID-19
pandemic. Longitudinal real-world studies on changes in the mental health of adolescents during …

Background On July 30, 2021, a third (booster) dose of the Pfizer BNT162b2 vaccine was
approved in Israel for individuals 60 years or older who had been fully vaccinated (ie, received …